PDE10A and schizophrenia: Patients with treatment-resistant schizophrenia do not have an increased level of dopamine synthesis capacity, as the patients do whose symptoms respond to conventional D2 blocking antipsychotic treatments.45 We did not observe any correlation between PDE10A expression and symptom severity in patients.